Drug intelligence / Profile preview

amitinib

Development stage: Unknown
Lead developer: Affiliated Cancer Hospital of Nanjing Medical University
Modality: Small Molecules
Administration: Oral, Enteral, Rectal

Overview

Amitinib is a pharmaceutical agent developed for the treatment of advanced non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) mutations. Clinical studies have indicated that amitinib offers comparable short-term efficacy and safety to first-line ositinib, while also demonstrating an improvement in patients' quality of life and a lower medical cost. Its mechanism of action is understood to involve targeting the specific EGFR mutations prevalent in this type of cancer.

Brand names: Ameile
Other names: Ametinib

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on amitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amitinib.

Explore the full profile